Editorial: Filovirus vaccines: What challenges are left?

Expert Review of Vaccines

Volumn 9, Issue 1, 2010, Pages 5-8

  Bukreyev, Alexander ^a   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; ENVELOPE PROTEIN; FILOVIRUS VACCINE; GLYCOPROTEIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PARAINFLUENZA VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VACCINE; VIRUS VACCINE; VIRUS VECTOR;

CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; EBOLA VIRUS; EDITORIAL; FILOVIRUS; HUMAN; IMMUNITY; IMMUNOGENICITY; MARBURG VIRUS; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; BIOLOGICAL WARFARE AGENT; FILOVIRIDAE; FILOVIRUS INFECTION; IMMUNOLOGY; PATHOGENICITY;

BIOLOGICAL WARFARE AGENTS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; VIRAL VACCINES;

EID: 74349131005     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.150     Document Type: Editorial

References (35)

1. Towner JS, Amman BR, Sealy TK et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5, e1000536 (2009).
2. Leroy EM, Kumulungui B, Pourrut X et al. Fruit bats as reservoirs of Ebola virus. Nature 438, 575-576 (2005).
3. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses (Volumn 1). Knipe DM, Howley PM, Griffin DE et al. (Eds). Lippincott-Raven Publishers, PA, USA (2007).
4. Jaax NK, Davis KJ, Geisbert TJ et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120, 140-155 (1996).
5. Pokhodiaev VA, Gonchar NI, Pshenichnov VA. An experimental study of the contact transmission of the Marburg virus. Vopr. Virusol. 36, 506-508 (1991).
6. Jaax N, Jahrling P, Geisbert T et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346, 1669-1671 (1995).
7. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76, 227-236 (1995).
8. Sergeev AN, Lub M, P'Iankova OG, Kotliarov LA. The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections. Antibiot. Khimioter. 40, 24-27 (1995).
9. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251, 28-37 (1998).
10. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8, 503-507 (2002).
11. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609 (2000).
12. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (2003).
13. Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21, 4071-4080 (2003).
14. Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786-790 (2005).
15. Daddario-DiCaprio KM, Geisbert TW, Ströher U et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367, 1399-1404 (2006).
16. Feldmann H, Jones SM, Daddario-Dicaprio KM et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3, e2 (2007).
17. Geisbert TW, Daddario-DiCaprio KM, Williams KJ et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 82, 5664-5668 (2008).
18. Geisbert TW, Geisbert JB, Leung A et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J. Virol. 83, 7296-7304 (2009).
19. Swenson DL, Wang D, Luo M et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15, 460-467 (2008).
20. Bukreyev A, Rollin PE, Tate MK et al. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81, 6379-6388 (2007).
21. Qiu X, Fernando L, Alimonti JB et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS ONE 4, e5547 (2009).
22. Warfield KL, Swenson DL, Olinger GG. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196(Suppl. 2), S430-S437 (2007).
23. Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol. 13, 1267-1277 (2006).
24. Karron RA, Belshe RB, Wright PF et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22, 394-405 (2003).
25. Johnson JE, Nasar F, Coleman JW et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in nonhuman primates. Virology 360, 36-49 (2007).
26. Garbutt M, Liebscher R, Wahl-Jensen V et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78, 5458-5465 (2004).
27. Bukreyev A, Yang L, Zaki SR et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80, 2267-2279 (2006).
28. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77, 799-803 (2003).
29. Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3, e3548 (2008).
30. Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. A paramyxovirusvectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377, 255-264 (2008).
31. Bukreyev A, Marzi A, Feldmann F et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 383, 348-361 (2009).
32. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7, 393-400 (2009).
33. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196(Suppl. 2), S400-S403 (2007).
34. + T cells specific for respiratory viruses in the human lung. J. Exp. Med. 202, 1433-1442 (2005).
35. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).